GPC3 targeted CAR-T(fuda)

GPC3靶向CAR-T(复旦)

Report date: 2026/05/21 20:00:22

NME

Base Information

Drug NameGPC3 targeted CAR-T(fuda)

Drug Alias Namechimeric antigen receptor modified autologous T cells targeting phosphatidylinositol proteoglycan-3 (GPC3)靶向磷脂酰肌醇蛋白多糖-3（GPC3）四代嵌合抗原受体修饰的自体 T 细胞

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derivedCell and gene therapy > Cell therapy > Donor > Autologous

Mechanisms of ActionAnti-Glypican-3

TargetsGlypican-3

Therapy Area/IndicationsCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesShanghai Zhongshan Hospital

China Registration ClassN/A

Develop Information

Active CompaniesShanghai Zhongshan Hospital

Inactive CompaniesN/A

Active IndicationsCarcinoma, Hepatocellular

Inactive IndicationsN/A

Other Information

ATC CodeN/A